Samantha Semenkow
Stock Analyst at Citigroup
(0.84)
# 3,722
Out of 4,761 analysts
40
Total ratings
28.12%
Success rate
-19.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLRN Acelyrin | Maintains: Neutral | $6 → $3 | $2.60 | +15.38% | 2 | Jan 7, 2025 | |
| BIOA BioAge Labs | Downgrades: Neutral | $45 → $7 | $4.50 | +55.56% | 2 | Dec 9, 2024 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $4.22 | +184.36% | 1 | Dec 2, 2024 | |
| ARGX argenx SE | Maintains: Buy | $512 → $635 | $644.48 | -1.47% | 4 | Oct 17, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $7 → $8 | $2.17 | +268.66% | 2 | Aug 9, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $21.62 | +43.39% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $3.01 | +398.34% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.45 | +788.30% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $3.19 | +338.87% | 6 | May 22, 2024 | |
| PRME Prime Medicine | Upgrades: Buy | $10 | $2.97 | +237.27% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $1.92 | +681.25% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $2.61 | +359.77% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $2.06 | +1,356.31% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $42.33 | +70.09% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $21.27 | +135.07% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $30.43 | +84.03% | 3 | Aug 9, 2023 |
Acelyrin
Jan 7, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.60
Upside: +15.38%
BioAge Labs
Dec 9, 2024
Downgrades: Neutral
Price Target: $45 → $7
Current: $4.50
Upside: +55.56%
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $4.22
Upside: +184.36%
argenx SE
Oct 17, 2024
Maintains: Buy
Price Target: $512 → $635
Current: $644.48
Upside: -1.47%
Allogene Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $2.17
Upside: +268.66%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $21.62
Upside: +43.39%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $3.01
Upside: +398.34%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.45
Upside: +788.30%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $3.19
Upside: +338.87%
Prime Medicine
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $2.97
Upside: +237.27%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.92
Upside: +681.25%
Apr 8, 2024
Maintains: Buy
Price Target: $9 → $12
Current: $2.61
Upside: +359.77%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $2.06
Upside: +1,356.31%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $42.33
Upside: +70.09%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $21.27
Upside: +135.07%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $30.43
Upside: +84.03%